Copyright
©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Dec 14, 2014; 20(46): 17265-17278
Published online Dec 14, 2014. doi: 10.3748/wjg.v20.i46.17265
Published online Dec 14, 2014. doi: 10.3748/wjg.v20.i46.17265
Country | Prevalence rate of HCV infection | Risk factors (≥10%) | Most frequent (≥10%) genotype(s) (%) | |
Three top (or less) | Level of confidence1 | |||
Egypt | 14.90% | Parenteral injections with multiuse syringe for schistosomiasis | High | 4 (93) |
Blood transfusion | ||||
Needle reuse | ||||
Italy | 5.20% | Parenteral injections with multiuse syringe for popular therapies | Intermediate | 1 (62) |
Blood transfusion | 2 (27) | |||
IDU | ||||
Pakistan | 4.70% | Syringe/needle reuse | High | 3 (68) |
Surgery/dental work | 1 (12) | |||
Blood transfusion | ||||
Taiwan | 4.40% | Medical injection | High | 1 (48) |
Blood transfusion | 2 (40) | |||
Acupuncture | ||||
Romania | 3.50% | Dental work | Intermediate | 1 (99) |
Surgery | ||||
Blood transfusion | ||||
Thailand | 2.80% | IDU | Intermediate | 3 (53) |
Tattooing | 1 (33) | |||
Blood transfusion | ||||
Spain | 2.64% | Surgery/dental work | Intermediate | 1 (65) |
Syringe reuse | 3 (20) | |||
IDU | ||||
Vietnam | 2%-2.9% | Blood transfusion | Low | 1 (47) |
IDU | 6 (47) | |||
Tattooing | ||||
Russia | 2%-2.5% | Blood transfusion | Intermediate | 1 (56) |
IDU | 3 (35) | |||
Acupuncture/tattooing | ||||
Israel | 1.96% | Blood transfusion | Intermediate | 1 (70) |
IDU | 3 (20) | |||
Poland | 1.90% | Blood transfusion | Low | 1 (58) |
Healthcare-related occupational exposure | 3 (31) | |||
IDU | ||||
Czech Republic | 1.5%-2% | IDU | Intermediate | 1 (79) |
Blood transfusion | 3 (20) | |||
Surgery | ||||
Switzerland | 1.25%-1.75% | IDU | High | 1 (51) |
Healthcare-related occupational exposure | 3 (30) | |||
Blood transfusion | ||||
Portugal | 1.50% | IDU | Low | 1 (52) |
Surgery | 3 (34) | |||
Sexual contacts | ||||
China | 1%-1.9% | Syringe/needle reuse | Low | 1 (68) |
Blood transfusion | 2 (14) | |||
Esophageal balloon | 6 (13) | |||
Greece | 1%-1.9% | IDU | Intermediate | 1 (47) |
Blood transfusion | 3 (27) | |||
4 (15) | ||||
India | 1%-1.9% | Blood transfusion | Intermediate | 3 (62) |
Syringe/needle reuse | 1 (31) | |||
Healthcare-related occupational exposure | ||||
Japan | 1%-1.9% | Blood transfusion | Intermediate | 1 (63) |
Syringe/needle reuse | 2 (25) | |||
IDU | ||||
Saudi Arabia | 1%-1.9% | Blood transfusion | Low | 4 (74) |
Parenteral injections with multiuse syringe for schistosomiasis | 1 (14) | |||
Tattooing | ||||
Syria | 1%-1.9% | Blood transfusion | Intermediate | 4 (59) |
Hemodialysis | 1 (29) | |||
Tattooing | 5 (10) | |||
Brazil | 1.40% | IDU and nasal drugs | Not available | 1 (65) |
Syringe/needle reuse | 3 (30) | |||
Healthcare-related occupational exposure | ||||
Australia | 1.30% | IDU | High | 3 (31) |
1 (14) | ||||
South Korea | 1.30% | Blood transfusion | Intermediate | 1 (50) |
History of endoscopy | 2 (45) | |||
Tattooing | ||||
Canada | 1.01% | IDU | Intermediate | 1 (60) |
Blood transfusion | 3 (22) | |||
2 (15) | ||||
Scotland | 1.00% | IDU | High | 1 (47) |
Blood transfusion | 3 (47) | |||
Tattooing | ||||
Turkey | 1.00% | Blood transfusion | Low | 1 (97) |
Surgery | ||||
Dental work | ||||
France | 0.84% | IDU and nasal drugs | Intermediate | 1 (57) |
3 (21) | ||||
Norway | 0.70% | IDU | High | 1 (61) |
3 (28) | ||||
2 (11) | ||||
England/Wales | 0.60% | IDU | High | 1 (45) |
3 (40) | ||||
Hungary | 0.60% | Surgery | Low | 1 (97) |
Blood transfusion | ||||
Tattooing | ||||
Sweden | 0.59% | IDU | High | 1 (45) |
3 (34) | ||||
2 (19) | ||||
Germany | 0.40% | IDU | High | 1 (62) |
Blood transfusion | 3 (28) |
Year of identification of the index case | Country | Occupation of HCW | Infected patients (n) | Infected (in case of look-back study) | Risk factor(s) identified | Ref. |
1991 | United States | Technician of an ambulatory surgical center | Approximately 40 | NA | IDU | [74] |
1992-1994 | Spain | Cardiothoracic surgeon | 5 | 2.25% | EPPs (cardiac valve replacement) | [75] |
1994 | United Kingdom | Cardiothoracic surgeon | 1 | 0.36% | EPPs | [76] |
1996 | United States | Anesthesiologist | 1 | 0.28% | Probable IDU | [77] |
Contaminated by another patient | ||||||
1996 | France | Not precised for confidentiality reasons | 1 | NA | EPPs (coronary artery replacement surgery) | [78] |
1998 | Germany | Anesthesiologist assistant | 5 | NA | Contaminated by another patient via an unprotected wound on hand | [79] |
Failure to use standard precautions (notably lack of gloving) | ||||||
1998 | Spain | Anesthesiologist | 217 to 275 over a 10-yr period | NA | IDU | [80,81] |
1999 | United Kingdom | Gynecologist-obstetrician | 8 over a 20-yr period | 0.18% | EPPs | [82-84] |
1999 | United Kingdom | General surgeon | 4 | 0.29% | NA | [84] |
1999 | United Kingdom | General surgeon | 2 | 0.27% | NA | [85] |
2000 | Germany | Orthopedic surgeon | 1 | 0.48% | EPPs | [86] |
2000 | Germany | Gynecologist-obstetrician | 1 over a 7-yr period | 0.04% | EPPs | [87] |
Failure to use standard precautions | ||||||
2000 | United States | Cardiothoracic surgeon | 14 over a 10-yr period | 1.49% | EPPs | [88] |
2001 | United Kingdom | Gynecologist-obstetrician | 1 | NA | EPPs | [89] |
2001 | Germany | Anesthesiologist | 3 | NA | Failure to use standard precautions (notably lack of gloving) | [90] |
2003 | Israel | Anesthesiologist | 33 | NA | IDU | [91] |
2004 | United States | Nurse anesthetist | 15 | NA | IDU | [92] |
2005 | United Kingdom | Gynecologist-obstetrician | 1 | NA | EPPs | [93] |
2005 | United Kingdom | Gynecologist-obstetrician | 1 | NA | EPPs | [93,94] |
Not specified | United Kingdom | Anesthesiologist | 1 | NA | None | [95] |
Prevention of patient to patient HCV transmission | Prevention of patient to HCW HCV transmission | Prevention of HCW to patient HCV transmission | |
Standard Precautions | X | X | X |
Work practice controls | X | X | X |
Engineered safety devices for injections | X | X | |
Use of single-use devices for injections | X | ||
Biological screening of blood products, tissue and grafts | X | ||
Restriction of activity of infected providers | X | ||
Antiviral treatment of infected providers | X |
- Citation: Pozzetto B, Memmi M, Garraud O, Roblin X, Berthelot P. Health care-associated hepatitis C virus infection. World J Gastroenterol 2014; 20(46): 17265-17278
- URL: https://www.wjgnet.com/1007-9327/full/v20/i46/17265.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i46.17265